ESMO BREAST CANCER 2026
SERD therapy demonstrates robust anti-proliferative activity in young patients with ER-positive/HER2-negative early breast cancer
Encouraging results with giredestrant support the future use of SERD-based endocrine strategies in this setting
Chemotherapy-free adjuvant treatment preserves quality of life in HER2-positive early breast cancer
A pathological complete response-guided approach enables treatment optimisation in a selected population with HER2-positive breast cancer in the PHERGain-2 study
Liquid biopsy has the potential to improve patients’ lives across the entire spectrum of breast cancer
The 2026 ESMO Breast Cancer Awardee, Daniel F. Hayes, reflects on the future of biomarker research in the field
How to sequence antibody–drug conjugates in metastatic breast cancer? Target switching alone may not be the answer
The first prospective phase II trials evaluating TOPO1 ADC after prior TOPO1 ADC therapy confirm the emergence of cross-resistance
The role of ctDNA surveillance is still uncertain in early breast cancer
Data from two novel studies further support the feasibility of this approach, although its clinical utility has yet to be determined
Towards a chemotherapy-free future in breast cancer?
Recent studies support treatment optimisation for improving patients’ quality of life, but its implementation in clinical practice remains limited
AI & DIGITAL ONCOLOGY
Customised app shows promise for monitoring prostate cancer patients in real-time
A pilot study reports high levels of acceptance and compliance despite an older patient population
Why AI-powered trial matching alone will not fix oncology trial recruitment
AI-powered trial matching helps identify relevant trials faster, but recruitment often fails beyond the algorithm. Limited cross-site trial discovery, outdated recruitment information and fragmented referral pathways continue to prevent potentially eligible patients from participating in relevant trials.
Can AI chatbots effectively support patients with cancer during treatments?
Early findings suggest potential benefits in symptom monitoring, but highlight usability challenges and added burden on clinical workflows
OPINIONS
Can digital tools improve personalised support for adolescents and young adults with cancer?
Ivana Bozovic-Spasojevic
The management of invasive lobular breast cancer is evolving
Rinath Jeselsohn
Phenotypic profiling in pancreatic cancer: promise meets practical limits
Alejandro González Sánchez
Novel emerging targets, new treatment opportunities
Jonathan Lim
Overcoming resistance to immunotherapy in NSCLC?
Alessandra Curioni Fontecedro
OPINIONS
Can digital tools improve personalised support for adolescents and young adults with cancer?
Ivana Bozovic-Spasojevic
The management of invasive lobular breast cancer is evolving
Rinath Jeselsohn
Phenotypic profiling in pancreatic cancer: promise meets practical limits
Alejandro González Sánchez
Novel emerging targets, new treatment opportunities
Jonathan Lim
Overcoming resistance to immunotherapy in NSCLC?
Alessandra Curioni Fontecedro